Please use this identifier to cite or link to this item:
http://sgc.anlis.gob.ar/handle/123456789/2449
Title: | Lidocaine reinforces the anti-inflammatory action of dexamethasone on myeloid and epithelial cells activated by inflammatory cytokines or SARS-CoV-2 infection | Authors: | Elizagaray, Maia Lina Mazitelli, Ignacio Pontoriero, Andrea Baumeister, Elsa Docena, Guillermo Raimondi, Clemente Correger, Enrique Rumbo, Martín |
Keywords: | SARS-CoV-2;COVID-19;Dexametasona;Inflamación;Interferón;Lidocaína | Issue Date: | 7-Aug-2022 | Journal: | Biomedical journal | Abstract: | Severe cases of COVID-19 that require admission to the ICU and mechanical ventilation assistance show a high mortality rate with currently few therapeutic options available. Severe COVID-19 is characterized by a systemic inflammatory condition, also called "cytokine storm", which can lead to various multi-organ complications and ultimately death. Lidocaine, a safe local anesthetic that given intravenously is used to treat arrhythmias, has long been reported to have an anti-inflammatory and pro-homeostatic activity. |
URI: | https://www.sciencedirect.com/science/article/pii/S2319417022001196?via%3Dihub http://sgc.anlis.gob.ar/handle/123456789/2449 |
DOI: | 10.1016/j.bj.2022.07.008 |
Appears in Collections: | Publicaciones INEI |
Show full item record
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.